SOURCE: Equity Spotlight

July 31, 2012 07:30 ET

Immunovative, Inc. (OTCBB: IMUN) Launches Corporate Site and ImmuNews Monthly Newsletter

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the EQUITY SPOTLIGHT

NEW YORK, NY--(Marketwire - Jul 31, 2012) - The following is an investment opinion issued on Immunovative, Inc. (OTCBB: IMUN), Dendreon Corp (NASDAQ: DNDN), MannKind Corp (NASDAQ: MNKD) and NewLink Genetics (NASDAQ: NLNK). Immunovative (OTCBB: IMUN) has announced the launch of their new corporate website with information on their technology, product candidates management team and videos. The company has also announced their monthly newsletter, ImmuNews, which has been designed to educate shareholders and friends of happenings in the rapidly developing field of cancer immunotherapy.

Memorial Sloan-Kettering Cancer Center calls immunotherapy research a "key approach to the future of cancer treatment." Companies like Dendreon (NASDAQ: DNDN), MannKind (NASDAQ: MNKD) and NewLink Genetics (NASDAQ: NLNK) along with Immunovative are all exploring ways to apply the body's natural immune system to fight and reject cancer and other diseases by inducing, enhancing or suppressing the immune response.

In June 2008, it was announced that doctors from the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle had successfully treated a skin cancer patient by using immune cells cloned from a patient's own immune system which were then re-injected into the patient, the patient was free of tumors with 8 weeks of the treatment.

For more information on Immunovative, please visit

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Equity Spotlight one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information